With ~20% of DLBCL harboring PD-L1 positive lymphomas, the presence of B2M alterations may be important in ICI directed against the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) interaction in R/R DLBCL [125,126]. The gene discussed is B2M; the disease is lymphoma.